Impaired fibrinolytic function secondary to elevated plasma
|
|
- Mervin Manning
- 5 years ago
- Views:
Transcription
1 Plasminogen Activator Inhibitor-1 4G/5G Polymorphism and Risk of Stroke Replicated Findings in Two Nested Case Control Studies Based on Independent Cohorts Per-Gunnar Wiklund, MD; Lennart Nilsson, MD, PhD; Sofie Nilsson Ardnor, MD; Per Eriksson, PhD; Lars Johansson, MD, PhD; Birgitta Stegmayr, PhD; Anders Hamsten, MD, PhD; Dan Holmberg, PhD; Kjell Asplund, MD, PhD Background and Purpose Impaired fibrinolytic function secondary to elevated plasminogen activator inhibitor-1 (PAI-1) levels has been implicated in ischemic stroke. PAI-1 levels are determined by genetic factors and environmental factors, triglyceride levels in particular. The aim of this study was to investigate the common functional 4/5 guanosine (4G/5G) polymorphism in the promoter region of the PAI-1 gene and the risk of stroke. Methods A nested case control study design was applied, using baseline data for 2 independent cohorts obtained at population-based surveys in northern Sweden. In study A, there were 113, and in study B, there were 275 individuals without major concomitant disease at baseline who later experienced a first-ever stroke. Blood samples obtained at baseline were analyzed for potential risk factors, including the 4G/5G polymorphism of the PAI-1 gene. Results The 4G allele of the PAI-1 polymorphism was associated with an increased risk of future ischemic stroke in both studies (odds ratio [OR] of 4G homozygosity, 1.87; 95% CI, 1.12 to 3.15 in study A; OR of 4G homozygosity, 1.56; 95% CI, 1.12 to 2.16 in study B). Individuals with the combination of hypertriglyceridemia and 4G homozygosity were at the greatest risk of developing stroke. Multiple logistic regression analysis identified 4G homozygosity, systolic blood pressure, and diabetes as independent predictors of ischemic stroke. Conclusions Identical findings in 2 independent studies strongly suggest a true and clinically important association between PAI-1 4G/5G genotype and risk of future ischemic stroke. The observed modification of the genotype effect by triglycerides may be interpreted as a gene environment interaction. (Stroke. 2005;36: ) Key Words: genetics plasminogen activator inhibitor-1 polymorphism stroke Impaired fibrinolytic function secondary to elevated plasma plasminogen activator inhibitor-1 (PAI-1) activity is associated with coronary heart disease, 1 and PAI-1 levels are consistently elevated in blood samples collected during the acute phase of ischemic stroke. 2 4 However, when samples are obtained before stroke, the power of PAI-1 levels to predict future stroke may be limited. 5 Across different populations, plasma levels of PAI-1 antigen are associated with a 4/5 guanosine (4G/5G) polymorphism in the promoter region of the PAI-1 gene. People homozygous for the 4G allele have the highest and 5G homozygotes have the lowest PAI-1 levels. 6,7 The relationship between 4G/5G polymorphism of the PAI-1 gene and stroke is unclear. It has been reported that the 4G/4G genotype confers an increased risk of stroke, 8 but other investigators have reported the same genotype to be neutral or even protective in terms of stroke risk. 4,9 12 High PAI-1 levels are linked to several components of the insulin resistance syndrome, most notably hypertriglyceridemia. 1 There may be a genetic determinant of the association between PAI-1 and triglycerides, in that a triglyceride response element has been identified in the promoter region of the PAI-1 gene. 13 There are many reasons why results of association studies in common disorders are difficult to replicate. There may be bias from selected patient populations, inappropriate controls, or misclassification of outcome. 14 Inadequate sample size may give rise to false-negative results, and there may exist differences between populations (eg, allelic heterogeneity). In stroke, with complex interactions between genetics, lifestyle, Received January 26, 2005; final revision received May 20, 2005; accepted May 31, From the Department of Public Health and Clinical Medicine (P-G.W., L.J., B.S., K.A.), Umeå University Hospital, Sweden; Atherosclerosis Research Unit (L.N., P.E., A.H.), King Gustav V Research Institute, Karolinska Hospital, Stockholm, Sweden; Department of Cardiology (L.N.), Heart Center, University Hospital, Linköping, Sweden; and Department of Medical Clinical Genetics (S.N.A., D.H.), Umeå University, Sweden. The first 2 authors contributed equally. Correspondence to Dr Per-Gunnar Wiklund, Department of Medicine, University Hospital, SE Umeå, Sweden. pg.wiklund@medicin.umu.se 2005 American Heart Association, Inc. Stroke is available at DOI: /01.STR
2 1662 Stroke August 2005 and social and environmental factors, it is obvious that genetic factors may have a different impact depending on the population burden of nongenetic stroke risk factors. In the present study, we tried to rectify some of the problems in previous studies. A population-based nested case control approach was used (ie, blood samples donated before stroke were analyzed), thereby avoiding problems of patient selection. Fatal as well as nonfatal cases were included after careful validation of clinical diagnoses. Matched controls were selected from the same background population. The findings of 1 stroke population were replicated in an independent stroke population. The aims of this study were to investigate the role of 4G/5G PAI-1 polymorphism in the causation of stroke and to explore the interaction between 4G/5G genotype and hypertriglyceridemia. Materials and Methods Study Population All subjects had been participants in population-based cardiovascular risk factor surveys in which blood samples and a broad range of interview data were collected. Surveys were conducted in northern Sweden. Screenings within the framework of the World Health Organization Monitoring Trends Determinants in Cardiovascular Disease (WHO MONICA) Project 15 were performed in 1986, 1990, 1994, and In all, 6952 randomly selected men and women in the age group of 25 to 74 years participated in the MONICA surveys. In parallel, men and women in Västerbotten County were asked to participate in a health survey (the same design as the MONICA population surveys) the year they turned 30, 40, 50, or 60 years of age. During the period January 1, 1985, to September 20, 2000, people participated. Participants in the MONICA and the Västerbotten surveys consented in writing to donate a blood sample stored at 80 C at the Northern Sweden Medical Research Bank for future research. Case Ascertainment and Validation Since 1985, a population-based stroke registry (ages 25 to 74 years) covering the same area as the risk factor surveys has been kept at the Northern Sweden MONICA Center. Procedures for case ascertainment were described in detail previously. 16 Data on subtype of stroke (ischemic or hemorrhagic) was based on CT scan, and subarachnoidal hemorrhages were excluded. The present studies used a nested case control design that included all individuals who experienced a first-ever stroke at 75 years of age after having participated in either the MONICA or Västerbotten health surveys. Thus, all patients provided baseline information and donated blood samples before the stroke event, and the population-based stroke registry ensured that all stroke events were prospectively included. included 157 patients with first-ever stroke events occurring during the period January 1, 1985, to August 31, 1996, and study B, which covered September 1, 1996, to September 20, 2000, included 427 stroke cases. Both studies used the same inclusion and exclusion criteria, and individuals with previous myocardial infarction (n 15 versus 55), a cancer diagnosis (n 13 versus 29), or insufficient amount of blood in the sample at baseline (n 16 versus 68) were excluded. After exclusion, 113 (91 ischemic, 19 hemorrhagic, and 3 unspecified strokes; 71 men and 42 women) and 275 (229 ischemic, 42 hemorrhagic, and 4 unspecified stroke; 157 men and 118 women) cases remained for analysis in the 2 studies, respectively. Two controls for each case were selected among participants in the same health surveys and matched for sex, age ( 2 years), and domicile. Control subjects were excluded under the same criteria as the cases. The studies were approved by the research ethics committee of Umeå University and the data handling procedures by the National Computer Data Inspection Board. Risk Factors, Biochemical Analyses, and Genotyping Baseline data included age, smoking status, height, weight, blood pressure, and presence of diabetes mellitus. A diagnosis of diabetes was self-reported or the results of a glucose tolerance test according to older WHO criteria. 17 Elevated blood pressure was defined as systolic blood pressure 140 mm Hg or diastolic blood pressure 90 or antihypertensive treatment. Fasting glucose and total serum cholesterol were determined at baseline. In study A, serum triglycerides were measured enzymatically, and PAI-1 antigen was determined using an ELISA with kits from Biopool AB (Imulyse PAI-1). DNA was isolated from whole blood or buffy coats. Genotyping of the PAI-1 4G/5G promoter polymorphism was performed using the method described by Margaglione et al 18 in study A. In study B, primers and probes were supplied by Assays-by-Design Service (Applied Biosystems). Polymerase chain reaction was run with the manufacturer-recommended TaqMan protocol with 10 ng of genomic DNA on an Applied Biosystems PRISM 7900 HT Sequence Detector System (Perkin Elmer). The sequences were VIC probe: VICCTGACTCCCCCACGT; FAM probe: 6FAMACTC- CCCACGTGTC; forward primer: GCCAGACAAGGTTGTTGA- CACA; and reverse primer: GCCGCCTCCGATGATACA. Statistical Methods Conditional logistic regression analyses, appropriate for this kind of 1:2 matched case control study design, were used in the main analyses to identify predictors of stroke. Odds ratios (ORs) are presented with corresponding 95% confidence limits. Baseline characteristics were compared between cases and controls using simple conditional logistic regression. To adjust for classical known stroke risk factors, a multiple model was used to test the effect of the genotype. In the complementary analyses (ie, analyzes of cases and controls separately) and analyses of subgroups defined by a specific genotype or level of serum triglycerides, where matching no longer applies because of splitting of the stratas, 2-tailed t tests were used for continuous variables and Pearson s 2 tests for categorical variables. A P value 0.05 was considered statistically significant. SPSS version 12.0 was used in the analysis. Results Baseline Characteristics For the 2 studies, Table 1 shows baseline characteristics of individuals who subsequently had a first-ever stroke and of matched controls who remained free of cardiovascular disease during follow-up. In the 2 studies, stroke occurred on average 30 and 59 months, respectively, after participation in the cardiovascular risk factor survey. Cases had higher systolic and diastolic blood pressures and higher fasting plasma glucose than controls in both studies. More cases than controls had a diagnosis of diabetes. In study B, with more statistical power, body mass index (BMI) and serum cholesterol were significantly higher in cases, and current smoking was more prevalent. Serum triglyceride levels and PAI-1 levels were measured only in study A and showed elevated serum triglycerides in stroke patients. PAI-1 4G/5G Promoter Genotype Genotyping for the PAI-1 4G/5G promoter polymorphism was performed in 329 of the 339 participants in study A and in 809 of the 824 subjects in study B. Genotyping was not possible because of technical problems in 10 (2 cases and 8
3 Wiklund et al PAI-1 Polymorphism and Risk of Stroke 1663 TABLE 1. Baseline Characteristics of Stroke Patients Versus Matched Controls in the 2 Studies Mean ( SD) or % Mean ( SD) or % Variable Stroke Patients (n 113) Controls (n 226) P Value Stroke Patients (n 275) Controls (n 549) P Value Age, years 55.2 ( 7.6) 55.2 ( 7.6) matched 55.0 ( 8.3) 54.8 ( 8.3) matched Married/cohabitant 78% 84% % 78% 0.38 Level of education Primary 58% 51% 49% 50% Secondary 31% 36% 37% 33% University 12% 12% 14% 16% Systolic blood pressure, mm Hg 148 ( 21) 138 ( 19) ( 20) 136 ( 18) Diastolic blood pressure, mm Hg 91 ( 10) 86 ( 10) ( 10) 85 ( 9) Fasting P-glucose, mmol/l 5.7 ( 1.7) 5.3 ( 1.2) ( 1.4) 5.3 ( 1.0) 0.02 BMI, kg/m ( 4.2) 26.3 ( 4.0) ( 4.3) 25.9 ( 3.5) S-Cholesterol, mmol/l 6.4 ( 1.2) 6.3 ( 1.3) ( 1.4) 6.2 ( 1.2) 0.02 S-Triglycerides, mmol/l 1.8 ( 1.2) 1.5 ( 0.8) NA NA NA P-PAI-1 antigen, ug/l 38.0 ( 22.8) 35.2 ( 20.0) 0.24 NA NA NA Diabetes mellitus 19 (17%) 11 (5%) (11%) 20 (4%) Smoking status, % Never 50% 56% 50% 55% Past 25% 26% 25% 25% Current 25% 18% % 20% 0.05 controls) and 15 subjects (8 cases and 7 controls), respectively. The genotype distributions were in Hardy Weinberg equilibrium and are shown in Table 2. 4G homozygosity was more common among stroke cases, the difference reaching statistical significance in study A (P 0.018) but not in study B (P 0.061). When cases were subgrouped according to stroke subtype, the overrepresentation of 4G homozygotes in the ischemic phenotype group was greater and found in both studies (P and P 0.008, respectively). Patients with hemorrhagic stroke did not show any overt difference in PAI-1 genotype distribution compared with controls, but the statistical power to detect a difference was low. Smoking habits, blood pressure, serum lipid and lipoprotein concentrations, and plasma glucose level did not differ according to PAI-1 genotype in either cases or controls (data not shown). TABLE 2. PAI-1 Genotypes and PAI-1 Allele Frequencies in Stroke Cases and Controls The OR of 4G/4G genotype for ischemic stroke was 1.87 (95% CI, 1.12 to 3.15) in study A. This was replicated in study B (OR, 1.56; 95% CI, 1.12 to 2.16). Elevated blood pressure and diabetes also conferred increased risk of ischemic stroke in both studies. A small but significant rise in stroke risk was seen for BMI and serum cholesterol in study B. A multiple conditional logistic regression model, including 4G homozygosity, elevated blood pressure, diabetes, and current smoking applied to the 2 studies found these variables, apart from smoking, to be associated independently with increased risk of future ischemic stroke (Table 3). Interaction Between PAI-1 Genotype and Serum Triglycerides Because in vivo and in vitro studies have suggested an interaction between triglycerides and PAI-1 4G/5G genotype, Ischemic (n 89) Stroke Patients Controls Stroke Patients Controls Hemorrhagic (n 19) Unspecified (n 3) All (n 111) Ischemic (n 222) Hemorrhagic (n 41) Unspecified (n 4) All (n 267) (n 218) (n 542) PAI-1 genotype 4G/4G 42 (47%) 6 (32) 2 50 (45%) 67 (31%) 94 (42%) 8 (20%) (38%) 174 (32%) 4G/5G 33 (37%) 9 (47%) 1 43 (39%) 109 (50%) 85 (38%) 23 (56%) (42%) 261 (48%) 5G/5G 14 (16%) 4 (21%) 0 18 (16%) 42 (19%) 43 (19%) 10 (24%) 0 53 (20%) 107 (20%) PAI-1 allele frequency 4G G
4 1664 Stroke August 2005 TABLE 3. ORs for Ischemic Stroke; Multiple Conditional Logistic Regression OR (95% CI) P Value OR (95% CI) P Value 4G/4G 1.79 ( ) ( ) Elevated blood pressure 2.58 ( ) ( ) Diabetes 5.26 ( ) ( ) Current smoking 0.99 ( ) ( ) 0.16 we investigated whether such an interaction could be of importance for the occurrence of stroke in study A. When subjects were subgrouped according to serum triglyceride level (cut-off of 1.7 mmol/l), the association of the PAI-1 4G allele with stroke was found to be confined to hypertriglyceridemic individuals ( ; 2 df; P 0.034). Conversely, serum triglycerides discriminated between cases and controls in 4G homozygotes (OR, 2.50 [95% CI, 1.13 to 5.53]; P 0.022) but not in heterozygotes or 5G homozygotes (OR, 1.33 [95% CI, 0.72 to 2.46]; P 0.36). In study A, we then applied a conditional regression model including an interaction factor of triglycerides and genotype as predictor of ischemic stroke. After adjustment for elevated blood pressure, diabetes, and smoking, this factor was found to be associated with ischemic stroke (P 0.036). The excess risk was confined to individuals with the combination triglyceride 1.7 mmol/l 4G/4G (OR, 3.58 [95% CI, 1.27 to 10.09]; P 0.016). PAI-1 antigen was measured in study A. There was an association between PAI-1 genotype and plasma PAI-1 antigen level ( g/l in 4G homozygotes, in heterozygotes, and in 5G homozygotes, cases and controls analyzed together), with a significant difference between 4G and 5G homozygotes (P 0.038). Discussion In these 2 prospective nested case control studies, the 4G allele of the PAI-1 4G/5G promoter polymorphism was associated with an increased risk of future ischemic stroke. The single base pair 4G/5G polymorphism in the PAI-1 promoter is common 7 and has been shown to influence the level of transcription of the PAI-1 gene in vitro in endothelial cells. 19 The 4G allele, having a higher transcriptional activity than the 5G allele, has been associated with enhanced plasma PAI-1 activity. 19,20 Apart from impaired fibrinolytic capacity attributable to high levels of circulating PAI-1, the local tissue effects are not fully understood, but PAI-1 seems to influence processes of smooth muscle cell proliferation, plague, and matrix remodeling in the direction of promoting as well as protecting against atherothrombosis. 21 Our findings that the PAI-1 4G allele is linked to increased risk of ischemic stroke only in hypertriglyceridemic individuals and that serum triglycerides is a predictor of future stroke only in 4G homozygotes are consistent with in vivo and in vitro studies. Hypertriglyceridemia is associated with increased plasma PAI-1 levels, 22 and the interaction of triglycerides with plasma PAI-1 activity is dependent on the 4G/5G polymorphism. 20 This is caused by a very-low density lipoprotein inducible transcription factor binding to a site in the PAI-1 promoter overlapping the 4G/5G polymorphic site. 13 Thus, part of the risk of stroke attributed to hypertriglyceridemia might be mediated by genotype-specific influences on PAI-1. It may seem surprising that PAI-1 genotype was a stronger predictor of future stroke than plasma PAI-1 antigen, but these levels are known to be influenced by several other metabolic, inflammatory, and vascular factors, 23 and this may reduce the capacity of PAI-1 antigen measurements to predict stroke. 24 Although an association between polymorphism of the PAI-1 gene and stroke has been shown previously, 8 most studies have failed to confirm a relationship, 4,9 12 and indeed, a meta-analysis has shown the 5G/5G PAI-1 genotype to be associated with increased risk of stroke. 25 There are several possible explanations for the discrepant results, the most obvious being differences in study population and design. An advantage of the nested case control design is the prospective property with data collection before the stroke event. This eliminates the risks of recall bias, missing information in fatal cases, and changes in exposure in nongenetic variables caused by the occurrence of stroke itself. The weakness of this approach is that lifestyle and social factors may change during the follow-up. The relatively short median interval from participation in the risk factor surveys and the stroke event (30 and 59 months in the 2 studies) make this less of a problem. The need for replication of associations before evidence is declared as convincing is increasingly recognized in clinical genetic studies. 14,26 If nonsystematic biases exist in an initial study, they are unlikely to be the same when the study is replicated. 14 One of the strengths of the present work is that the findings of 1 study population was replicated in a second population, with the same hypothesis being tested and both studies showing that 4G/5G promoter polymorphism predicted future risk of ischemic stroke. The 2 populations were independent in the sense that they were separated in time and predefined before any analyses were performed. However, they were performed in the same geographical area, which leaves a possibility that the findings are specific to this population. We calculate the population attributable risk of 4G homozygosity to 17%. In summary, the present study suggests that PAI-1 genotype influences the risk of future stroke and that knowledge of an individuals PAI-1 4G/5G genotype may be more predictive than a single measurement of the plasma level of PAI-1. The excess risk in carriers of the 4G allele is modified by triglyceride levels.
5 Wiklund et al PAI-1 Polymorphism and Risk of Stroke 1665 Acknowledgments We are indebted to the Northern Sweden MONICA Project, the Västerbotten Intervention Project, the Northern Sweden Medical Research Bank, and the funds supporting these projects. The present study obtained supplementary funding from the Swedish Research Council, the Strategic Research Foundation and the Swedish Heart- Lung Foundation. Göran Hallmans is responsible for organizing and maintaining the Medical Biobank, and Lars Weinehall is organizing the Västerbotten Intervention Project. References 1. Hamsten A, Eriksson P, Karpe F, Silveira A. Relationships of thrombosis and fibrinolysis to atherosclerosis. Curr Opin Lipidol. 1994;5: Margaglione M, Di Minno G, Grandone E, Vecchione G, Celentano E, Cappucci G, Grilli M, Simone P, Panico S, Mancini M. Abnormally high circulation levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in patients with a history of ischemic stroke. Arterioscler Thromb. 1994;14: Lindgren A, Lindoff C, Norrving B, Åstedt B, Johansson BB. Tissue plasminogen activator and plasminogen activator inhibitor-1 in stroke patients. Stroke. 1996;27: Catto AJ, Carter AM, Stickland M, Bamford JM, Davies JA, Grant PJ. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G promoter polymorphism and levels in subjects with cerebrovascular disease. Thromb Haemost. 1997;77: Johansson L, Jansson JH, Boman K, Nilsson TK, Stegmayr B, Hallmans G. Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke. Stroke. 2000;31: Hamsten A, Eriksson P. Fibrinolysis and atherosclerosis. Baillieres Clin Haematol. 1995;8: Festa A, D Agostino R Jr, Rich SS, Jenny NS, Tracy RP, Haffner SM. Promoter (4G/5G) plasminogen activator inhibitor-1 genotype and plasminogen activator inhibitor-1 levels in blacks, Hispanics, and non- Hispanic whites: the Insulin Resistance Atherosclerosis Study. Circulation. 2003;107: Bang CO, Park HK, Ahn MY, Shin HK, Hwang KY, Hong SY. 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene and insertion/deletion polymorphism of the tissue-type plasminogen activator gene in atherothrombotic stroke. Cerebrovasc Dis. 2001;11: Hindorff LA, Schwartz SM, Siscovick DS, Psaty BM, Longstreth WT Jr, Reiner AP. The association of PAI-1 promoter 4G/5G insertion/deletion polymorphism with myocardial infarction and stroke in young women. J Cardiovasc Risk. 2002;9: Roest M, van der Schouw YT, Banga JD, Tempelman MJ, de Groot PG, Sixma JJ, Grobbee DE. Plasminogen activator inhibitor 4G polymorphism is associated with decreased risk of cerebrovascular mortality in older women. Circulation. 2000;101: Endler G, Lalouschek W, Exner M, Mitterbauer G, Haring D, Mannhalter C. The 4G/4G genotype at nucleotide position -675 in the promotor region of the plasminogen activator inhibitor 1 (PAI-1) gene is less frequent in young patients with minor stroke than in controls. Br J Haematol. 2000;110: Hoekstra T, Geleijnse JM, Kluft C, Giltay EJ, Kok FJ, Schouten EG. 4G/4G genotype of PAI-1 gene is associated with reduced risk of stroke in elderly. Stroke. 2003;34: Eriksson P, Nilsson L, Karpe F, Hamsten A. Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia. Arterioscler Thromb Vasc Biol. 1998;18: Colhoun HM, McKeigue PM, Davey Smith G. Problems of reporting genetic associations with complex outcomes. Lancet. 2003;361: Kuulasmaa K, Tunstall-Pedoe H, Dobson A, Fortmann S, Sans S, Tolonen H, Evans A, Ferrario M, Tuomilehto J. Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA project populations. Lancet. 2000;355: Stegmayr B, Lundberg V, Asplund K. The events registration and survey procedures in the Northern Sweden MONICA project. Scand J Public Health Suppl. 2003;61: WHO Study Group. Diabetes mellitus. World Health Organization Technical Report, series Margaglione M, Grandone E, Cappucci G, Colaizzo D, Giuliani N, Vecchione G, d Addedda M, Di Minno G. An alternative method for PAI-1 promoter polymorphism (4G/5G) typing. Thromb Haemost. 1997; 77: Eriksson P, Kallin B, van t Hooft FM, Båvenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A. 1995;92: Panahloo A, Mohamed-Ali V, Lane A, Green F, Humphries SE, Yudkin JS. Determinants of plasminogen activator inhibitor 1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene. Diabetes. 1995;44: Roest M, Banga JD. Editorial comment genetic make-up for increased PAI-1 expression protects against stroke. Stroke. 2003;34: Hamsten A, Wiman B, de Faire U, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med. 1985;313: Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med. 2000;342: Folsom AR. Hemostatic risk factors for atherothrombotic disease: an epidemiologic view. Thromb Haemost. 2001;86: Casas JP, Hingorani AD, Bautista LE, Sharma P. Meta-analysis of genetic studies in ischemic stroke: thirty-two genes involving approximately cases and controls. Arch Neurol. 2004;61: Little J, Bradley L, Bray MS, Clyne M, Dorman J, Ellsworth DL, Hanson J, Khoury M, Lau J, O Brien TR, Rothman N, Stroup D, Taioli E, Thomas D, Vainio H, Wacholder S, Weinberg C. Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations. Am J Epidemiol. 2002;156:
Plasminogen activator inhibitor type 1 (PAI-1), which
4G/4G Genotype of PAI-1 Gene Is Associated With Reduced Risk of Stroke in Elderly Tiny Hoekstra, PhD; Johanna M. Geleijnse, PhD; Cornelis Kluft, PhD; Erik J. Giltay, PhD; Frans J. Kok, PhD; Evert G. Schouten,
More informationThe majority of ischemic strokes occur because of thrombotic
Fibrinolytic Gene Polymorphism and Ischemic Stroke Katarina Jood, MD; Per Ladenvall, MD, PhD; Anna Tjärnlund-Wolf, PhD; Claes Ladenvall, MSc; Maria Andersson, MSc; Staffan Nilsson, PhD; Christian Blomstrand,
More informationGenetic aspects of stroke Association and linkage studies in a northern Swedish population
Genetic aspects of stroke Association and linkage studies in a northern Swedish population Per-Gunnar Wiklund Copyright 2005 by Per-Gunnar Wiklund ISSN 0346-6612 ISBN 91-7305-999-4 Printed by Print & Media,
More informationThe underlying cause of stroke in most cases is an
High Proinsulin Levels Precede First-Ever Stroke in a Nondiabetic Population Bernt Lindahl, MD, PhD; Bo Dinesen, MSc; Mats Eliasson, MD, PhD; Michael Røder, MD; Göran Hallmans, MD, PhD; Birgitta Stegmayr,
More informationJournal of the American College of Cardiology Vol. 34, No. 6, by the American College of Cardiology ISSN /99/$20.
Journal of the American College of Cardiology Vol. 34, No. 6, 1999 1999 by the American College of Cardiology ISSN 0735-1097/99/$20.00 Published by Elsevier Science Inc. PII S0735-1097(99)00424-6 Lack
More informationRisk Factors for Ischemic Stroke: Electrocardiographic Findings
Original Articles 232 Risk Factors for Ischemic Stroke: Electrocardiographic Findings Elley H.H. Chiu 1,2, Teng-Yeow Tan 1,3, Ku-Chou Chang 1,3, and Chia-Wei Liou 1,3 Abstract- Background: Standard 12-lead
More informationCigarette smoking is pandemic, affecting large proportions
Smokeless Tobacco as a Possible Risk Factor for Stroke in Men A Nested Case-Control Study Kjell Asplund, MD; Salmir Nasic, BSc; Urban Janlert, MD; Birgitta Stegmayr, PhD Background and Purpose Snuff and
More informationRegence. Medical Policy Manual. Date of Origin: May Topic: Genetic Testing for Lipoprotein(a) Variant(s) as a Decision Aid for Aspirin Treatment
Regence Medical Policy Manual Topic: Genetic Testing for Lipoprotein(a) Variant(s) as a Decision Aid for Aspirin Treatment Date of Origin: May 2013 Section: Genetic Testing Last Reviewed Date: June 2013
More informationPlasminogen Activator Inhibitor-1 and Angiotensin I Converting Enzyme Gene Polymorphism in Patients With Hypertension
AJH 1998;11:235 239 Plasminogen Activator Inhibitor-1 and Angiotensin I Converting Enzyme Gene Polymorphism in Patients With Hypertension Jing-Ren Jeng, Horng-Jyh Harn, Kuo-Cheu Yueh, Chii-Yuan Jeng, and
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/20497 holds various files of this Leiden University dissertation. Author: Siegerink, Bob Title: Prothrombotic factors and the risk of myocardial infarction
More informationLow level of tissue plasminogen activator activity in non-diabetic patients with a first myocardial infarction
Journal of Internal Medicine 2005; 258: 13 20 Low level of tissue plasminogen activator activity in non-diabetic patients with a first myocardial infarction D. LUNDBLAD 1,2,B.DINESEN 3,A.RAUTIO 1,2,M.E.RØDER
More informationThe Framingham Coronary Heart Disease Risk Score
Plasma Concentration of C-Reactive Protein and the Calculated Framingham Coronary Heart Disease Risk Score Michelle A. Albert, MD, MPH; Robert J. Glynn, PhD; Paul M Ridker, MD, MPH Background Although
More informationAssociations between matrix metalloproteinase gene polymorphisms and the development of cerebral infarction
Associations between matrix metalloproteinase gene polymorphisms and the development of cerebral infarction J.H. Zhao 1,2, Y.M. Xu 1, H.X. Xing 2, L.L. Su 2, S.B. Tao 2, X.J. Tian 2, H.Q. Yan 2 and S.B.
More informationGeographic Distribution of Stroke Incidence Within an Urban Population
Geographic Distribution of Stroke Incidence Within an Urban Population Relations to Socioeconomic Circumstances and Prevalence of Cardiovascular Risk Factors Gunnar Engström, MD, PhD; Ingela Jerntorp,
More informationA Clinical Study of Plasma Fibrinogen Level in Ischemic Stroke
Original Article Print ISSN: 2321-6379 Online ISSN: 2321-595X DOI: 10.17354/ijss/2018/24 A Clinical Study of Plasma Fibrinogen Level in Ischemic Stroke Bingi Srinivas 1, B Balaji 2 1 Assistant Professor,
More informationESPEN Congress Florence 2008
ESPEN Congress Florence 2008 Severe obesity - Session organised in conjunction with ASPEN The SOS study Setting the Scene A. Thorell (Sweden) The SOS study Setting the Scene Anders Thorell MD, PhD Associate
More informationAssociation of plasma uric acid with ischemic heart disease and blood pressure:
Association of plasma uric acid with ischemic heart disease and blood pressure: Mendelian randomization analysis of two large cohorts. Tom M Palmer, Børge G Nordestgaard, DSc; Marianne Benn, Anne Tybjærg-Hansen,
More informationThe risk of myocardial infarction and sudden cardiac death amongst snuff users with or without a previous history of smoking
Original Article doi: 10.1111/j.1365-2796.2007.01813.x The risk of myocardial infarction and sudden cardiac death amongst snuff users with or without a previous history of smoking P. Wennberg 1,2,3, M.
More informationSupplementary Online Content
Supplementary Online Content Pedersen SB, Langsted A, Nordestgaard BG. Nonfasting mild-to-moderate hypertriglyceridemia and risk of acute pancreatitis. JAMA Intern Med. Published online November 7, 2016.
More informationHomozygosity for 807 T Polymorphism in 2 Subunit of Platelet 2 1 Is Associated With Increased Risk of Cardiovascular Mortality in High-Risk Women
Homozygosity for 807 T Polymorphism in 2 Subunit of Platelet 2 1 Is Associated With Increased Risk of Cardiovascular Mortality in High-Risk Women Mark Roest, PhD; Jan Dirk Banga, MD, PhD; Diederick E.
More informationThe target blood pressure in patients with diabetes is <130 mm Hg
Controversies in hypertension, About Diabetes diabetes and and metabolic Cardiovascular syndrome Risk ESC annual congress August 29, 2011 The target blood pressure in patients with diabetes is
More informationSupplementary Online Content
Supplementary Online Content Kavousi M, Leening MJG, Nanchen D, et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines
More informationPAI-1 Gene 4G/5G Genotype: A Risk Factor for Thrombosis in Vessels of Internal Organs
American Journal of Hematology 71:89 93 (2002) PAI-1 Gene 4G/5G : A Risk Factor for Thrombosis in Vessels of Internal Organs Gunay Balta,* Cigdem Altay, and Aytemiz Gurgey Hacettepe University, Faculty
More informationDuring the hyperinsulinemic-euglycemic clamp [1], a priming dose of human insulin (Novolin,
ESM Methods Hyperinsulinemic-euglycemic clamp procedure During the hyperinsulinemic-euglycemic clamp [1], a priming dose of human insulin (Novolin, Clayton, NC) was followed by a constant rate (60 mu m
More informationGuidelines on cardiovascular risk assessment and management
European Heart Journal Supplements (2005) 7 (Supplement L), L5 L10 doi:10.1093/eurheartj/sui079 Guidelines on cardiovascular risk assessment and management David A. Wood 1,2 * 1 Cardiovascular Medicine
More informationIschemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010
Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories
More informationDiabetes Mellitus: A Cardiovascular Disease
Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular
More informationOptimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden
Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Cardiovascular Disease Prevention (CVD) Three Strategies for CVD
More informationNon-fasting lipids and risk of cardiovascular disease in patients with diabetes mellitus
Diabetologia (2011) 54:73 77 DOI 10.1007/s00125-010-1945-z SHORT COMMUNICATION Non-fasting lipids and risk of cardiovascular disease in patients with diabetes mellitus S. van Dieren & U. Nöthlings & Y.
More informationAssociation between the CYP11B2 gene 344T>C polymorphism and coronary artery disease: a meta-analysis
Association between the CYP11B2 gene 344T>C polymorphism and coronary artery disease: a meta-analysis Y. Liu, H.L. Liu, W. Han, S.J. Yu and J. Zhang Department of Cardiology, The General Hospital of the
More informationDiabetologia 9 Springer-Verlag 1991
Diabetologia (1991) 34:590-594 0012186X91001685 Diabetologia 9 Springer-Verlag 1991 Risk factors for macrovascular disease in mellitus: the London follow-up to the WHO Multinational Study of Vascular Disease
More informationBehind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL
Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL Sung-Joon Lee, PhD Division of Food Science Institute of Biomedical Science and Safety Korea University Composition of Lipoproteins:
More informationRisk factors for microvascular and macrovascular complications in men and women with type 2 diabetes
ORIGINAL PAPER Risk factors for microvascular and macrovascular complications in men and women with type 2 diabetes Per Erik Wändell Family Medicine Stockholm, Karolinska Institutet, Huddinge, Sweden.
More informationRole of inflammatory parameters in the susceptibility of cerebral thrombosis
Role of inflammatory parameters in the susceptibility of cerebral thrombosis X.F. Qi 1, T.J. Feng 2, P. Yang 1, H.Y. Feng 3, P. Zhang 2, L.Y. Kong 1, D.L. Liang 1, P.F. Li 4, W. Na 5, Y.W. Li 5 and Y.
More informationChapter 4 INSIG2 Polymorphism and BMI in Indian Population
Chapter 4 INSIG2 Polymorphism and BMI in Indian Population 4.1 INTRODUCTION Diseases like cardiovascular disorders (CVD) are emerging as major causes of death in India (Ghaffar A et. al., 2004). Various
More informationJournal of the American College of Cardiology Vol. 48, No. 2, by the American College of Cardiology Foundation ISSN /06/$32.
Journal of the American College of Cardiology Vol. 48, No. 2, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.03.043
More informationTargeting Glucose Metabolism to Stop Strokes IRIS: Insulin Resistance In Stroke study
Targeting Glucose Metabolism to Stop Strokes IRIS: Insulin Resistance In Stroke study Professor Gary Ford Chief Executive Officer, Oxford Academic Health Science Network Consultant Stroke Physician, Oxford
More informationEvolving patterns of tobacco use in northern Sweden
Journal of Internal Medicine 2003; 253: 660 665 Evolving patterns of tobacco use in northern Sweden B. RODU 1, B. STEGMAYR 2, S. NASIC 2, P. COLE 3 & K. ASPLUND 2 From the 1 Department of Pathology, School
More informationThe problem of uncontrolled hypertension
(2002) 16, S3 S8 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh The problem of uncontrolled hypertension Department of Public Health and Clinical Medicine, Norrlands
More informationTissue plasminogen activator antigen and coronary heart disease
European Heart Journal (2004) 25, 252 259 Clinical research Tissue plasminogen activator antigen and coronary heart disease Prospective study and meta-analysis G.D.O. Lowe a *, J. Danesh b, S. Lewington
More informationPeripheral Arterial Occlusive Disease- The Challenge in patients with diabetes
Peripheral Arterial Occlusive Disease- The Challenge in patients with diabetes Ashok Handa Reader in Surgery and Consultant Surgeon Nuffield Department of Surgery University of Oxford Introduction Vascular
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationThe American Diabetes Association estimates
DYSLIPIDEMIA, PREDIABETES, AND TYPE 2 DIABETES: CLINICAL IMPLICATIONS OF THE VA-HIT SUBANALYSIS Frank M. Sacks, MD* ABSTRACT The most serious and common complication in adults with diabetes is cardiovascular
More informationFatality of Future Coronary Events Is Related to Inflammation-Sensitive Plasma Proteins
Fatality of Future Coronary Events Is Related to Inflammation-Sensitive Plasma Proteins A Population-Based Prospective Cohort Study Gunnar Engström, MD; Bo Hedblad, MD; Lars Stavenow, MD; Patrik Tydén,
More informationARTICLE. Marie Eriksson & Kjell Asplund & Bart Van Rompaye & Mats Eliasson
Diabetologia (213) 56:2181 2186 DOI 1.17/s125-13-2983- ARTICLE Differences in cardiovascular risk factors and socioeconomic status do not explain the increased risk of death after a first stroke in diabetic
More informationAssociation between the interleukin-1β gene -511C/T polymorphism and ischemic stroke: an updated meta-analysis
Association between the interleukin-1β gene -511C/T polymorphism and ischemic stroke: an updated meta-analysis W. Yan, Z.Y. Chen, J.Q. Chen and H.M. Chen Department of Neurology, Ningbo No. 2 Hospital,
More informationThe inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema
The inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema Dept Cardiology, Leiden University Medical Center, Leiden,
More informationFasting insulin and risk of cerebral infarction in a Japanese general population: The Jichi Medical School Cohort Study
Neurology Asia 2013; 18(4) : 343 348 ORIGINAL ARTICLES Fasting insulin and risk of cerebral infarction in a Japanese general population: The Jichi Medical School Cohort Study 1 Yuji Kaneda MD, 2 Shizukiyo
More information김광일 서울대학교의과대학내과학교실 분당서울대학교병원내과
치매예방을위한만성질환관리전략 김광일 서울대학교의과대학내과학교실 분당서울대학교병원내과 A sharp rise in the death rate from Alzheimer s disease Ivan Casserly & Eric Topol, Lancet 2004 Potential for primary prevention of Alzheimer s disease Alzheimer
More informationA: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups
A: Epidemiology update Evidence that LDL-C and CRP identify different high-risk groups Women (n = 27,939; mean age 54.7 years) who were free of symptomatic cardiovascular (CV) disease at baseline were
More informationMolecular mechanisms & clinical consequences. of prothrombin mutations. A.J. Hauer
Molecular mechanisms & clinical consequences of prothrombin mutations A.J. Hauer 07-12-2018 Prothrombin & the coagulation cascade Coagulation factor II, thrombin. Prothrombin is synthesized in the liver
More informationThere are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk?
There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk? Michael Davidson M.D. FACC, Diplomate of the American Board of Lipidology Professor,
More informationCVD Prevention, Who to Consider
Continuing Professional Development 3rd annual McGill CME Cruise September 20 27, 2015 CVD Prevention, Who to Consider Dr. Guy Tremblay Excellence in Health Care and Lifelong Learning Global CV risk assessment..
More informationCONTENT SUPPLEMENTARY FIGURE E. INSTRUMENTAL VARIABLE ANALYSIS USING DESEASONALISED PLASMA 25-HYDROXYVITAMIN D. 7
CONTENT FIGURES 3 SUPPLEMENTARY FIGURE A. NUMBER OF PARTICIPANTS AND EVENTS IN THE OBSERVATIONAL AND GENETIC ANALYSES. 3 SUPPLEMENTARY FIGURE B. FLOWCHART SHOWING THE SELECTION PROCESS FOR DETERMINING
More informationPrevention of Cardiovasular Diseases
Role and Significance of In-Vitro-Diagnostics in the Healthcare Systems of the Future Prevention of Cardiovasular Diseases Michael Walter Charité University Medicine, Berlin & Unfallkrankenhaus Berlin
More informationRisk of developing diabetes is inversely related to lung function: a population-based cohort study.
Risk of developing diabetes is inversely related to lung function: a population-based cohort study. Engström, Gunnar; Janzon, Lars Published in: Diabetic Medicine DOI: 10.1046/j.1464-5491.2002.00652.x
More informationCardiovascular risk factors differ between rural and urban Sweden: the 2009 Northern Sweden MONICA cohort
Lindroth et al. BMC Public Health 2014, 14:825 RESEARCH ARTICLE Open Access Cardiovascular risk factors differ between rural and urban Sweden: the 2009 Northern Sweden MONICA cohort Martin Lindroth 1,
More informationAPPENDIX B: LIST OF THE SELECTED SECONDARY STUDIES
APPENDIX B: LIST OF THE SELECTED SECONDARY STUDIES Main systematic reviews secondary studies on the general effectiveness of statins in secondary cardiovascular prevention (search date: 2003-2006) NICE.
More informationElevated levels of tissue-type plasminogen activator (tpa)
Tissue Plasminogen Activator, Fibrin D-Dimer, and Insulin Resistance in the Relatives of Patients With Premature Coronary Artery Disease Joseph D. Mills, Michael W. Mansfield, Peter J. Grant Abstract Elevated
More informationSHORT COMMUNICATION. K. Lukacs & N. Hosszufalusi & E. Dinya & M. Bakacs & L. Madacsy & P. Panczel
Diabetologia (2012) 55:689 693 DOI 10.1007/s00125-011-2378-z SHORT COMMUNICATION The type 2 diabetes-associated variant in TCF7L2 is associated with latent autoimmune diabetes in adult Europeans and the
More informationDoes Socioeconomic Status or Acculturation Modify the Association Between Ethnicity and Hypertension Treatment Before Stroke?
Does Socioeconomic Status or Acculturation Modify the Association Between Ethnicity and Hypertension Treatment Before Stroke? Deborah A. Levine, MD, MPH; Lewis B. Morgenstern, MD; Kenneth M. Langa, MD,
More informationLower Contribution of Factor V Leiden or G Mutations to Ischemic Stroke in Patients With Clinical Risk Factors: Pair-Matched Case-Control Study
Lower Contribution of Factor V Leiden or G202104 Mutations to Ischemic Stroke in Patients With Clinical Risk Factors: Pair-Matched Case-Control Study Davor Eterović, PhD,* Marina Titlić, MD, Viktor Čulić,
More informationSeveral prospective studies have reported inverse relationships
Occurrence and Prognostic Significance of Ventricular Arrhythmia Is Related to Pulmonary Function A Study From Men Born in 1914, Malmö, Sweden Gunnar Engström, MD, PhD; Per Wollmer, MD, PhD; Bo Hedblad,
More informationAssociation between Raised Blood Pressure and Dysglycemia in Hong Kong Chinese
Diabetes Care Publish Ahead of Print, published online June 12, 2008 Raised Blood Pressure and Dysglycemia Association between Raised Blood Pressure and Dysglycemia in Hong Kong Chinese Bernard My Cheung,
More informationRisks and benefits of weight loss: challenges to obesity research
European Heart Journal Supplements (2005) 7 (Supplement L), L27 L31 doi:10.1093/eurheartj/sui083 Risks and benefits of weight loss: challenges to obesity research Donna Ryan* Pennington Biomedical Research
More informationHypertension is generally considered to be the most
Blood Pressure Control and Risk of Stroke A Population-Based Prospective Cohort Study Cairu Li, MD, PhD; Gunnar Engström, MD, PhD; Bo Hedblad, MD, PhD; Göran Berglund, MD, PhD; Lars Janzon, MD, PhD Background
More informationFasting or non fasting?
Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics Which is best to measure Lower continues
More informationAssociation between matrix metalloproteinase-9 rs polymorphism and development of coronary artery disease in a Chinese population
Association between matrix metalloproteinase-9 rs3918242 polymorphism and development of coronary artery disease in a Chinese population L.M. Qin 1, G.M. Qin 2, X.H. Shi 1, A.L. Wang 1 and H. Zuo 1 1 The
More informationSocial Patterning of Myocardial Infarction and Stroke in Sweden: Incidence and Survival
American Journal erf Epidemiology Copyright O 2000 by The Johns Hopkins University School of Hygiene and Public Hearth All rights reserved vol. 151, No. 3 Printed In U.S.A. Social Patterning of Myocardial
More informationfactor for recurrent myocardial infarction and death
Br Heart J 1991;66:351-5 Internal Medicine, SkellefteA Hospital, Sweden J-H Jansson Clinical Chemistry, UmeA University Hospital, Sweden T K Nilsson Internal Medicine, UmeA University Hospital, Sweden
More informationStroke Incidence and Mortality Rates 1987 to 2006 Related to Secular Trends of Cardiovascular Risk Factors in Gothenburg, Sweden
; Stroke Incidence and Mortality Rates 1987 to 2006 Related to Secular Trends of Cardiovascular Risk Factors in Gothenburg, Sweden Per Harmsen, MD; Lars Wilhelmsen, MD, PhD; Anders Jacobsson, BSc Background
More informationThe investigation of serum lipids and prevalence of dyslipidemia in urban adult population of Warangal district, Andhra Pradesh, India
eissn: 09748369, www.biolmedonline.com The investigation of serum lipids and prevalence of dyslipidemia in urban adult population of Warangal district, Andhra Pradesh, India M Estari, AS Reddy, T Bikshapathi,
More informationThe heavy impact of diabetes mellitus (DM) on the risk of,
Favorable Trends in the Incidence and Outcome in Stroke in Nondiabetic and Diabetic Subjects Findings From the Northern Sweden MONICA Stroke Registry in 1985 to 2003 Aslak Rautio, MD; Mats Eliasson, MD,
More informationSUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL A Meta-analysis of LDL-C, non-hdl-c, and apob as markers of cardiovascular risk. Slide # Contents 2 Table A1. List of candidate reports 8 Table A2. List of covariates/model adjustments
More informationJournal of the American College of Cardiology Vol. 37, No. 3, by the American College of Cardiology ISSN /01/$20.
Journal of the American College of Cardiology Vol. 37, No. 3, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)01172-4 Hyperinsulinemia
More informationHyperhomocysteinemia is known to be an. Methylenetetrahydrofolate Reductase Gene Polymorphism. Relation to Blood Pressure and Cerebrovascular Disease
AJH 1998;11:1019 1023 BRIEF COMMUNICATIONS Methylenetetrahydrofolate Reductase Gene Polymorphism Relation to Blood Pressure and Cerebrovascular Disease Yukiko Nakata, Tomohiro Katsuya, Seiju Takami, Noriyuki
More informationDyslipidemia, hypertension, smoking, and diabetes are
Inflammation-Sensitive Plasma Proteins and Incidence of Myocardial Infarction in Men With Low Cardiovascular Risk Gunnar Engström, Lars Stavenow, Bo Hedblad, Peter Lind, Patrik Tydén, Lars Janzon, Folke
More informationARIC Manuscript Proposal #1233. PC Reviewed: 4_/_10/07 Status: _A Priority: 2_ SC Reviewed: Status: Priority:
ARIC Manuscript Proposal #1233 PC Reviewed: 4_/_10/07 Status: _A Priority: 2_ SC Reviewed: Status: Priority: 1.a. Full Title: Subclinical atherosclerosis precedes type 2 diabetes in the ARIC study cohort
More informationVal-MARC: Valsartan-Managing Blood Pressure Aggressively and Evaluating Reductions in hs-crp
Página 1 de 5 Return to Medscape coverage of: American Society of Hypertension 21st Annual Scientific Meeting and Exposition Val-MARC: Valsartan-Managing Blood Pressure Aggressively and Evaluating Reductions
More informationPrognostic significance of blood pressure measured in the office, at home and during ambulatory monitoring in older patients in general practice
(2005) 19, 801 807 & 2005 Nature Publishing Group All rights reserved 0950-9240/05 $30.00 www.nature.com/jhh ORIGINAL ARTICLE Prognostic significance of blood pressure measured in the office, at home and
More informationCt=28.4 WAT 92.6% Hepatic CE (mg/g) P=3.6x10-08 Plasma Cholesterol (mg/dl)
a Control AAV mtm6sf-shrna8 Ct=4.3 Ct=8.4 Ct=8.8 Ct=8.9 Ct=.8 Ct=.5 Relative TM6SF mrna Level P=.5 X -5 b.5 Liver WAT Small intestine Relative TM6SF mrna Level..5 9.6% Control AAV mtm6sf-shrna mtm6sf-shrna6
More informationGlobal Coronary Heart Disease Risk Assessment of U.S. Persons With the Metabolic. Syndrome. and Nathan D. Wong, PhD, MPH
Diabetes Care Publish Ahead of Print, published online April 1, 2008 Global Coronary Heart Disease Risk Assessment of U.S. Persons With the Metabolic Syndrome Khiet C. Hoang MD, Heli Ghandehari, BS, Victor
More informationThe term metabolic syndrome has been proposed to
Relation Between the Metabolic Syndrome and Ischemic Stroke or Transient Ischemic Attack A Prospective Cohort Study in Patients With Atherosclerotic Cardiovascular Disease N. Koren-Morag, PhD; U. Goldbourt,
More informationCase Study: Chris Arden. Peripheral Arterial Disease
Case Study: Chris Arden Peripheral Arterial Disease Patient Presentation Diane is a 65-year-old retired school teacher She complains of left calf pain when walking 50 metres; the pain goes away after she
More informationAnnals of RSCB Vol. XVI, Issue 1
THE STUDY OF PROTHROBOTIC STATE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASES Oana Bădulescu 1, Codruţa Bădescu 2, Manuela Ciocoiu 1, Magda Bădescu 1 1 DEPARTMENT OF PATHOPHYSIOLOGY;
More information2) Cases and controls were genotyped on different platforms. The comparability of the platforms should be discussed.
Reviewers' Comments: Reviewer #1 (Remarks to the Author) The manuscript titled 'Association of variations in HLA-class II and other loci with susceptibility to lung adenocarcinoma with EGFR mutation' evaluated
More informationCarotid Artery Stenosis
Evidence-Based Approach to Carotid Artery Stenosis Seong-Wook Park, MD Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine, Seoul, Korea Carotid Artery Stenosis Carotid
More information(n=6279). Continuous variables are reported as mean with 95% confidence interval and T1 T2 T3. Number of subjects
Table 1. Distribution of baseline characteristics across tertiles of OPG adjusted for age and sex (n=6279). Continuous variables are reported as mean with 95% confidence interval and categorical values
More informationAutonomic nervous system, inflammation and preclinical carotid atherosclerosis in depressed subjects with coronary risk factors
Autonomic nervous system, inflammation and preclinical carotid atherosclerosis in depressed subjects with coronary risk factors Carmine Pizzi 1 ; Lamberto Manzoli 2, Stefano Mancini 3 ; Gigliola Bedetti
More informationIncidence of Obesity-Associated Cardiovascular Disease Is Related to Inflammation-Sensitive Plasma Proteins
Incidence of Obesity-Associated Cardiovascular Disease Is Related to Inflammation-Sensitive Plasma Proteins A Population-Based Cohort Study Gunnar Engström, Bo Hedblad, Lars Stavenow, Susanna Jonsson,
More informationT. Suithichaiyakul Cardiomed Chula
T. Suithichaiyakul Cardiomed Chula The cardiovascular (CV) continuum: role of risk factors Endothelial Dysfunction Atherosclerosis and left ventricular hypertrophy Myocardial infarction & stroke Endothelial
More informationNightmares, sleep and cardiac symptoms in the elderly
ORIGINAL ARTICLE Nightmares, sleep and cardiac symptoms in the elderly R. Asplund Family Medicine Stockholm, Karolinska Institute, Research and Development Unit (Jämtland County Council), Sweden, tel.:
More informationA total of 2,822 Mexican dyslipidemic cases and controls were recruited at INCMNSZ in
Supplemental Material The N342S MYLIP polymorphism is associated with high total cholesterol and increased LDL-receptor degradation in humans by Daphna Weissglas-Volkov et al. Supplementary Methods Mexican
More informationPatients with the metabolic syndrome are at increased risk
Clinical Investigation and Reports C-Reactive Protein, the Metabolic Syndrome, and Risk of Incident Cardiovascular Events An 8-Year Follow-Up of 14 719 Initially Healthy American Women Paul M Ridker, MD;
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationEffects of whole grain intake on weight changes, diabetes, and cardiovascular Disease
Effects of whole grain intake on weight changes, diabetes, and cardiovascular Disease Simin Liu, MD, ScD Professor of Epidemiology and Medicine Director, Center for Global Cardiometabolic Health Brown
More informationORIGINAL CONTRIBUTION. Obesity and Vascular Risk Factors at Midlife and the Risk of Dementia and Alzheimer Disease
ORIGINAL CONTRIBUTION Obesity and Vascular Risk Factors at Midlife and the Risk of Dementia and Alzheimer Disease Miia Kivipelto, MD, PhD; Tiia Ngandu, BM; Laura Fratiglioni, MD, PhD; Matti Viitanen, MD,
More informationAndrejs Kalvelis 1, MD, PhD, Inga Stukena 2, MD, Guntis Bahs 3 MD, PhD & Aivars Lejnieks 4, MD, PhD ABSTRACT INTRODUCTION. Riga Stradins University
CARDIOVASCULAR RISK FACTORS ORIGINAL ARTICLE Do We Correctly Assess the Risk of Cardiovascular Disease? Characteristics of Risk Factors for Cardiovascular Disease Depending on the Sex and Age of Patients
More informationRisk Associated with Various Definitions of Family History of Coronary Heart Disease
American Journal of Epidemiology Copyright 998 by The Johns Hopkins University School of Hygiene and Public Health All rights reserved Vol. 47, No. 2 Printed in U.S.A. Risk Associated with Various Definitions
More informationAssociation between the -77T>C polymorphism in the DNA repair gene XRCC1 and lung cancer risk
Association between the -77T>C polymorphism in the DNA repair gene XRCC1 and lung cancer risk B.B. Sun, J.Z. Wu, Y.G. Li and L.J. Ma Department of Respiratory Medicine, People s Hospital Affiliated to
More information